A study on drug delivery tracing with radiolabeled mesoporous hydroxyapatite nanoparticles conjugated with 2DG/DOX for breast tumor cells

BACKGROUND: Mesoporous nanoparticles have a great potential in targeted therapy approaches due to their ideal properties for encapsulation of various drugs, proteins and also biologically active molecules. MATERIAL AND METHODS: We used mesoporous hydroxyapatite (HA) nanoparticles as a drug carrier and developed radiolabeled mesoporous HA containing of 2-deoxy-D-glucose (2DG) and Doxorubicin (DOX) with technetium-99m (^99mTc) for imaging in in vitro and in vivo studies. RESULTS: 2DG and DOX in presence of mesoporous HA nanoparticles more reduced the fraction of viable cells in the MDA-MB-231, MCF-7 human and MC4-L2 Balb/c mice breast cancer cells. The radiochemical purity of the nano-2DG-DOX complex with^99mTc was calculated to 96.8%. The results of cellular uptake showed a 44.77% increase in uptake of the [^99mTc]-nano-2DG-DOX compared to the complex without nanoparticles (p < 0.001). CONCLUSIONS: Radioisotopic imaging demonstrated a high biochemical stability for [^99mTc]-nano-2DG-DOX complex. The results demonstrated that [^99mTc]-nano-2DG-DOX, may be used as an attractive candidate in cancer imaging and treatment managing.